Clinical and Molecular Features Associated with the Presence of Brain Metastases and Survival in Patients with Advanced Thyroid Cancer

Abstract Background Brain metastases in advanced thyroid cancer may be underrecognized due to lack of routine brain imaging. We characterized the clinical and molecular features, risk factors, and survival outcomes of patients with non-anaplastic follicular cell-derived thyroid carcinoma (FCDTC) with brain metastases. Methods This retrospective cohort study included patients with advanced non-anaplastic FCDTC treated in the Medical Oncology department at Princess Margaret Cancer Centre from 2007–2022. Clinicopathologic and treatment data were extracted from electronic records, and all tumors underwent targeted next-generation sequencing. Risk factors for brain metastasis were assessed using logistic regression, and overall survival was analyzed with Kaplan-Meier and Cox proportional hazards models. Results Of 187 patients with advanced non-anaplastic FCDTC, 32 (17%) were diagnosed with brain metastases. Dedicated brain imaging was performed in 56% of patients, and most metastases (78%) were asymptomatic and incidentally detected. Lung metastases were associated with higher risk of developing brain metastases (aOR 8.27, 95% CI 1.87-36.46). ARID2 mutations were enriched in patients with brain metastases (9% vs 1%, p = 0.02). Survival did not differ between patients with and without brain metastases. Patients with brain metastases who had an ECOG performance status ≥2 (aHR 8.42, 95% 1.96-36.11) or ≥ 4 brain metastases (aHR 5.43, 95% CI 1.51-19.48) had worse survival. Molecular alterations were not predictive of survival. Conclusion Brain metastases occurred more frequently than previously reported. Lung metastases were associated with higher risk of developing brain metastases, and performance status and lesion number were associated with survival. These findings support consideration of brain metastasis screening in advanced thyroid cancer and may inform future prognostic and treatment strategies.

Authors

Institutions

Publication Details

Journal
The Oncologist
Published
2026-05-28
DOI
https://doi.org/10.1093/oncolo/oyag211
Primary Topic
Thyroid Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical and Molecular Features Associated with the Presence of Brain Metastases and Survival in Patients with Advanced Thyroid Cancer

Thais Baccili Cury Megid, Anna M. Sawka, Vijithan Sugumar, Carly C. Barron et al.
The Oncologist
Thyroid Cancer Diagnosis and Treatment
article

Clinical and Molecular Features Associated with the Presence of Brain Metastases and Survival in Patients with Advanced Thyroid Cancer

Thais Baccili Cury Megid, Anna M. Sawka, Vijithan Sugumar, Carly C. Barron, Yangqing Deng, Aruz Mesci, Michael Yan, Jelena Lukovic, Sara Ladak, Lucy X Ma, Monika K Krzyzanowska, Ozgur Mete
article en

Abstract

Abstract Background Brain metastases in advanced thyroid cancer may be underrecognized due to lack of routine brain imaging. We characterized the clinical and molecular features, risk factors, and survival outcomes of patients with non-anaplastic follicular cell-derived thyroid carcinoma (FCDTC) with brain metastases. Methods This retrospective cohort study included patients with advanced non-anaplastic FCDTC treated in the Medical Oncology department at Princess Margaret Cancer Centre from 2007–2022. Clinicopathologic and treatment data were extracted from electronic records, and all tumors underwent targeted next-generation sequencing. Risk factors for brain metastasis were assessed using logistic regression, and overall survival was analyzed with Kaplan-Meier and Cox proportional hazards models. Results Of 187 patients with advanced non-anaplastic FCDTC, 32 (17%) were diagnosed with brain metastases. Dedicated brain imaging was performed in 56% of patients, and most metastases (78%) were asymptomatic and incidentally detected. Lung metastases were associated with higher risk of developing brain metastases (aOR 8.27, 95% CI 1.87-36.46). ARID2 mutations were enriched in patients with brain metastases (9% vs 1%, p = 0.02). Survival did not differ between patients with and without brain metastases. Patients with brain metastases who had an ECOG performance status ≥2 (aHR 8.42, 95% 1.96-36.11) or ≥ 4 brain metastases (aHR 5.43, 95% CI 1.51-19.48) had worse survival. Molecular alterations were not predictive of survival. Conclusion Brain metastases occurred more frequently than previously reported. Lung metastases were associated with higher risk of developing brain metastases, and performance status and lesion number were associated with survival. These findings support consideration of brain metastasis screening in advanced thyroid cancer and may inform future prognostic and treatment strategies.

The Oncologist
Sunnybrook Health Science Centre (CA), University Health Network (CA), University of Toronto (CA), Princess Margaret Cancer Centre (CA), Vitalité Health Network (CA)
Good health and well-being
Openalex Percentile: Top 6%
Thyroid Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.